These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25981342)

  • 1. Anti-A and anti-B titers in donor plasma, plasma pools, and immunoglobulin final products.
    McVey J; Baker D; Parti R; Berg R; Gudino M; Teschner W
    Transfusion; 2015 Jul; 55 Suppl 2():S98-104. PubMed ID: 25981342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor screening reduces the isoagglutinin titer in immunoglobulin products.
    Siani B; Willimann K; Wymann S; Marques Antunes A; Widmer E
    Transfusion; 2015 Jul; 55 Suppl 2():S95-7. PubMed ID: 26174905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-A and anti-B: what are they and where do they come from?
    Branch DR
    Transfusion; 2015 Jul; 55 Suppl 2():S74-9. PubMed ID: 26174901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products.
    Romberg V; Hoefferer L; El Menyawi I
    Transfusion; 2015 Jul; 55 Suppl 2():S105-9. PubMed ID: 26174887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis.
    Bellac CL; Hottiger T; Jutzi MP; Bögli-Stuber K; Sänger M; Hanschmann KM; Keller-Stanislawski B; Funk MB
    Transfusion; 2015 Jul; 55 Suppl 2():S13-22. PubMed ID: 26174892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening.
    Mallick R; Hubsch A; Barnes DG
    Transfusion; 2018 Dec; 58(12):2752-2756. PubMed ID: 30284263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.
    Gerber S; Gaida A; Spiegl N; Wymann S; Antunes AM; Menyawi IE; Zurbriggen B; Hubsch A; Imboden M
    BioDrugs; 2016 Oct; 30(5):441-451. PubMed ID: 27646589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening.
    Siani B; Willimann K; Wymann S; Marques AA; Widmer E
    Biol Ther; 2014 Dec; 4(1-2):15-26. PubMed ID: 24841428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products.
    Hoefferer L; Glauser I; Gaida A; Willimann K; Marques Antunes A; Siani B; Wymann S; Widmer E; El Menyawi I; Bolli R; Spycher M; Imboden M
    Transfusion; 2015 Jul; 55 Suppl 2():S117-21. PubMed ID: 26174889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations.
    Sakem B; Matozan K; Nydegger UE; Weigel G; Griesmacher A; Risch L
    Isr Med Assoc J; 2013 Oct; 15(10):617-21. PubMed ID: 24266088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group O blood donors in Iran: evaluation of isoagglutinin titers and immunoglobulin G subclasses.
    Arabi S; Moghaddam M; Pourfathollah AA; Aghaie A; Mosaed M
    Immunohematology; 2021 Mar; 37(1):5-12. PubMed ID: 33962489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal pooled plasma (Uniplas(®)) does not induce complement-mediated hemolysis of human red blood cells in vitro.
    Heger A; Brandstätter H; Prager B; Brainovic J; Cortes R; Römisch J
    Transfus Apher Sci; 2015 Feb; 52(1):128-35. PubMed ID: 23706313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of single donor platelet with low antibody titers for all patients.
    Romphruk AV; Cheunta S; Pakoate L; Kumpeera P; Sripara P; Paupairoj C; Romphruk A
    Transfus Apher Sci; 2012 Apr; 46(2):125-8. PubMed ID: 22365668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.
    Kahwaji J; Barker E; Pepkowitz S; Klapper E; Villicana R; Peng A; Chang R; Jordan SC; Vo AA
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):1993-7. PubMed ID: 19833910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-A and anti-B hemagglutinin depletion during Cohn purification process of 5% immunoglobulin.
    Salvatore A; Esin S; Batoni G; Ascione E; Farina C; Nardini C
    Transfusion; 2015 Jul; 55 Suppl 2():S110-6. PubMed ID: 26174888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant numbers of apheresis-derived group O platelet units have "high-titer" anti-A/A,B: implications for transfusion policy.
    Josephson CD; Mullis NC; Van Demark C; Hillyer CD
    Transfusion; 2004 Jun; 44(6):805-8. PubMed ID: 15157243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.
    Josephson CD; Castillejo MI; Grima K; Hillyer CD
    Transfus Apher Sci; 2010 Feb; 42(1):83-8. PubMed ID: 20034854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-A/B Antibody Titers in Group O Healthy Donors in Hainan Province Area].
    Yu S; Huang YW; Wang XX; Wu YQ; Lin MX; Yu Y; Luo Q
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):1138-43. PubMed ID: 26314460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study.
    Wallenhorst C; Patel A; Shebl A; Hubsch A; Simon TL; Martinez C
    Transfusion; 2020 Jul; 60(7):1381-1390. PubMed ID: 32488887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin M anti-A and anti-B titers in South Texas group O D+ male donors.
    Beddard R; Ngamsuntikul S; Wafford T; Aranda L
    Transfusion; 2019 Jul; 59(7):2207-2210. PubMed ID: 30897224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.